Inquest into the death of Jeffrey Stewart Olsen

64y · Male·Colonic adenocarcinoma and its treatment

Jeffrey Olsen, 64, died from acute capecitabine toxicity during adjuvant chemotherapy for Stage 3b colorectal cancer. Within three days of commencing treatment in September 2020, severe side effects including diarrhea, rash, and mucositis developed. Despite ceasing the drug and receiving intensive medical support including antibiotics, vasopressors, and ICU care, he rapidly deteriorated with neutropenic sepsis, acute kidney injury, multi-organ failure, and septic shock, dying after 14 days. The likely cause was an undetected DPD enzyme deficiency, preventing normal drug metabolism. The coroner found the care provided was appropriate by 2020 standards—DPD genetic testing was not routine, and the antidote uridine triacetate was unavailable in Australia. This case highlighted critical systemic gaps. Since his death, significant changes have occurred: DPD genotyping became publicly funded (November 2025) and nationally accessible, enabling pre-treatment screening; uridine triacetate is now stored nationally. Future patients can be identified before treatment and managed preventatively.